| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.81 MB | Adobe PDF |
Orientador(es)
Resumo(s)
A Toxina Botulínica tipo A (BoNT/A) é uma neurotoxina produzida pela bactéria Clostridium botulinum, reconhecida como uma das substâncias mais potentes e versáteis da medicina moderna (Kehayova et al., 2025). Inicialmente aplicada em contextos neuromusculares, a sua utilização expandiu-se amplamente para fins estéticos, devido à capacidade de reduzir temporariamente a contração muscular e suavizar rugas dinâmicas (Kehayova et al., 2025). O presente trabalho tem como objetivo analisar a eficácia, segurança e perspetivas futuras da BoNT/A na medicina estética, com base em evidência científica recente e regulamentação farmacêutica.
A pesquisa abrangeu revisões sistemáticas e ensaios clínicos que demonstram a previsibilidade dos resultados, o perfil de segurança favorável e a elevada satisfação dos utentes.
Os principais efeitos adversos descritos incluem ptose palpebral, edema e equimose, geralmente transitórios e associados a falhas técnicas (Lima et al., 2025). A prática segura depende do cumprimento das boas práticas de reconstituição, conservação e rastreabilidade, bem como da formação adequada dos profissionais (Kehayova et al., 2025). Conclui-se que a BoNT/A mantém-se como uma ferramenta estética eficaz e segura, cuja evolução técnica e regulamentar continuará a reforçar a confiança dos profissionais e dos pacientes na sua utilização (Santos et al., 2025).
Botulinum toxin type A (BoNT/A) is a neurotoxin produced by the bacterium Clostridium botulinum, recognized as one of the most potent and versatile substances in modern medicine (Kehayova et al., 2025). Initially applied in neuromuscular contexts, its use has expanded widely for aesthetic purposes due to its ability to temporarily reduce muscle contraction and smooth dynamic wrinkles (Kehayova et al., 2025). The present study aims to analyze the efficacy, safety, and future prospects of BoNT/A in aesthetic medicine, based on recent scientific evidence and pharmaceutical regulations. The research covered systematic reviews and clinical trials demonstrating the predictability of results, favorable safety profile, and high user satisfaction. The main adverse effects described include eyelid ptosis, edema, and ecchymosis, which are usually transient and associated with technical failures (Lima et al., 2025). Safe practice depends on compliance with good practices for reconstitution, storage, and traceability, as well as adequate training of professionals (Kehayova et al., 2025). It is concluded that botulinum toxin type A remains an effective and safe aesthetic tool, whose technical and regulatory evolution will continue to reinforce the confidence of professionals and patients in its use (Santos et al., 2025).
Botulinum toxin type A (BoNT/A) is a neurotoxin produced by the bacterium Clostridium botulinum, recognized as one of the most potent and versatile substances in modern medicine (Kehayova et al., 2025). Initially applied in neuromuscular contexts, its use has expanded widely for aesthetic purposes due to its ability to temporarily reduce muscle contraction and smooth dynamic wrinkles (Kehayova et al., 2025). The present study aims to analyze the efficacy, safety, and future prospects of BoNT/A in aesthetic medicine, based on recent scientific evidence and pharmaceutical regulations. The research covered systematic reviews and clinical trials demonstrating the predictability of results, favorable safety profile, and high user satisfaction. The main adverse effects described include eyelid ptosis, edema, and ecchymosis, which are usually transient and associated with technical failures (Lima et al., 2025). Safe practice depends on compliance with good practices for reconstitution, storage, and traceability, as well as adequate training of professionals (Kehayova et al., 2025). It is concluded that botulinum toxin type A remains an effective and safe aesthetic tool, whose technical and regulatory evolution will continue to reinforce the confidence of professionals and patients in its use (Santos et al., 2025).
Descrição
Dissertação para obtenção do grau de Mestre no Instituto Universitário Egas Moniz
Palavras-chave
Toxina botulínica tipo A Medicina estética Eficácia e segurança Farmacovigilância
